Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.32 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.31 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.31 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084792 | 0.76 | CXCR4 (0.38) | CACNA2D1CXCR4MAPKAPK2SLC6A2SLC6A4 | |
| SCHEMBL20279304 | 0.69 | NOS3 (0.39) | SCN8ACXCR4SLC6A4 | |
| SCHEMBL5574432 | 0.69 | CXCR4 (0.48) | SCN8ACXCR4RAB9A | |
| SCHEMBL15130898 | 0.69 | SIGMAR1 (0.50) | — | |
| SCHEMBL18160810 | 0.67 | NOS3 (0.42) | CXCR4SLC6A4 | |
| SCHEMBL28260787 | 0.67 | SMN1; SMN2 (0.41) | CACNA2D1MAPKAPK2SLC6A2SLC6A4NPC1 | |
| SCHEMBL825269 | 0.67 | NOS3 (0.42) | SCN8ACXCR4SLC6A4 | |
| SCHEMBL4363804 | 0.67 | CYP1A2 (0.43) | CXCR4RAB9A | |
| SCHEMBL28450031 | 0.67 | NOS3 (0.45) | SCN8ACXCR4SLC6A2SLC6A4 | |
| SCHEMBL2085001 | 0.66 | CXCR4 (0.42) | SCN8ACXCR4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863293-B2 | CXCR4 chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2011-01-04 | — | — | US | claimed |
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED CORPORATION (CA) | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255197-A1 | CXCR4 CHEMOKINE RECEPTOR BINDING COMPOUNDS | CXCR4, CXCR1, CXCR3 | CACNA2D1 3986/4885SCN8A 4681/4885HSPA5 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.